• Cingulate posted a Q2 net loss of USD 5.9 million, widening from USD 5 million a year earlier.
• R&D expense fell 44.9% to USD 1.5 million, while SG&A more than doubled to USD 3.9 million.
• Cash and cash equivalents rose to USD 28.4 million at June 30 from USD 11 million at Dec. 31.
• FDA issued a complete response letter on June 1 seeking additional CMC information for CTx-1301; no clinical safety or efficacy concerns were cited.
• Signed an exclusive services agreement with Prasco to set up commercial distribution; cash expected to fund operations into mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130830PRIMZONEFULLFEED9809060) on August 13, 2026, and is solely responsible for the information contained therein.